according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

### **SECTION 1. IDENTIFICATION**

Product name : Ertugliflozin / Metformin Formulation

Other means of identification : No data available

## Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

### **SECTION 2. HAZARDS IDENTIFICATION**

### GHS classification in accordance with the Hazardous Products Regulations

Acute toxicity (Oral) : Category 4

**GHS** label elements

Hazard pictograms



Signal Word : Warning

Hazard Statements : H302 Harmful if swallowed.

Precautionary Statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a doctor if you feel

unwell. Rinse mouth.

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

## Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 09/30/2023 04/14/2025 590547-00020 Date of first issue: 04/01/2016 5.2

### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
metformin hydrochlo- ride	No data availa- ble	1115-70-4	>= 60 - < 80 *
Cellulose	No data availa- ble	9004-34-6	>= 10 - < 30 *
Magnesium stearate	Octadecanoic acid, magnesi- um salt (2:1)	557-04-0	>= 1 - < 5 *
Ertugliflozin	No data availa- ble	1210344-83-4	>= 0.1 - < 1 *

Actual concentration or concentration range is withheld as a trade secret

#### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

Wash with water and soap. In case of skin contact

Get medical attention if symptoms occur.

In case of eye contact If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting unless directed to do

> so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

Harmful if swallowed.

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

#### **SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Specific hazards during fire

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protec- :

tive equipment and emergency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

### **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
metformin hydrochloride	1115-70-4	TWA	1 mg/m3 (OEB 1)	Internal
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Inhal- able)	10 mg/m³	CA BC OEL
		TWA (Respirable)	3 mg/m³	CA BC OEL
		TWAEV (in- halable dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWAEV (respirable aerosol frac- tion)	3 mg/m³	CA QC OEL
		TWA (Inhalable	10 mg/m³	ACGIH

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 04/14/2025 590547-00020 Date of first issue: 04/01/2016 5.2

		particulate matter)		
		TWA (Respirable particulate matter)	3 mg/m³	ACGIH
Ertugliflozin	1210344-83- 4	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm <sup>2</sup>	Internal

**Engineering measures** All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material Chemical-resistant gloves

Consider double gloving. Remarks

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

If exposure to chemical is likely during typical use, provide Hygiene measures

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Particle characteristics

Particle size : No data available

### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : I

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

### **SECTION 11. TOXICOLOGICAL INFORMATION**

### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

### **Acute toxicity**

Harmful if swallowed.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 1,337 mg/kg

Method: Calculation method

## **Components:**

metformin hydrochloride:

Acute oral toxicity : LD50 (Rat): 1,000 mg/kg

LD50 (Mouse): 1,450 - 3,500 mg/kg

LD50 (Monkey): 463 mg/kg

LD50 (Rabbit): 350 mg/kg

LD50 (Guinea pig): 500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 423

Assessment: The substance or mixture has no acute oral tox-

icity

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

**Ertugliflozin:** 

Acute oral toxicity : LD50 (Rat): 500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

## Skin corrosion/irritation

Not classified based on available information.

## **Components:**

### metformin hydrochloride:

Species : Rabbit

Result : Mild skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

**Ertugliflozin:** 

Result : Corrosive

### Serious eye damage/eye irritation

Not classified based on available information.

### **Components:**

### metformin hydrochloride:

Species : Rabbit

Result : Mild eye irritation

Magnesium stearate:

Species : Rabbit

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Result : No eye irritation

Remarks : Based on data from similar materials

**Ertugliflozin:** 

Result : Severe irritation

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

### Respiratory sensitization

Not classified based on available information.

### **Components:**

### Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig

Method : OECD Test Guideline 406

Result : negative

Remarks : Based on data from similar materials

**Ertugliflozin:** 

Test Type : Local lymph node assay (LLNA)

Result : Not a skin sensitizer.

### Germ cell mutagenicity

Not classified based on available information.

## Components:

## metformin hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro test

Test system: mouse lymphoma cells

Result: negative

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

### Cellulose:

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Remarks: Based on data from similar materials

**Ertugliflozin:** 

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat Result: negative

Carcinogenicity

Not classified based on available information.

**Components:** 

metformin hydrochloride:

Species : Mouse Exposure time : 91 weeks

Dose : 1500 mg/kg body weight

Result : negative

Species : Rat, male
Application Route : Oral
Exposure time : 104 weeks

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Dose : 900 mg/kg body weight

Result : negative

Species : Rat, female

Application Route : Oral

Exposure time : 104 weeks

LOAEL : 900 mg/kg body weight

Result : negative

Target Organs : Uterus (including cervix)

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

**Ertugliflozin:** 

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

### Reproductive toxicity

Not classified based on available information.

#### Components:

### metformin hydrochloride:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 600 mg/kg body weight

Result: No effects on fertility.

Effects on fetal development : Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 600 mg/kg body weight

Result: No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 04/14/2025 590547-00020 Date of first issue: 04/01/2016 5.2

Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 140 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Test Type: One-generation reproduction toxicity study Effects on fertility

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Magnesium stearate:

Test Type: Combined repeated dose toxicity study with the Effects on fertility

reproduction/developmental toxicity screening test

Species: Rat

**Application Route: Ingestion** 

Method: OECD Test Guideline 422

Result: negative

Remarks: Based on data from similar materials

Test Type: Embryo-fetal development Effects on fetal development

Species: Rat

**Application Route: Ingestion** 

Result: negative

Remarks: Based on data from similar materials

**Ertugliflozin:** 

Test Type: Fertility/early embryonic development Effects on fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight Remarks: Maternal toxicity observed.

No significant adverse effects were reported

Test Type: Fertility/early embryonic development

Species: Rabbit Application Route: Oral

Fertility: NOAEL: 200 mg/kg body weight

Remarks: No significant adverse effects were reported

Effects on fetal development Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight Remarks: Adverse developmental effects were observed

Test Type: Embryo-fetal development

Species: Rabbit

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Application Route: Oral

Developmental Toxicity: NOAEL: 250 mg/kg body weight Remarks: No significant adverse effects were reported

### STOT-single exposure

Not classified based on available information.

### **STOT-repeated exposure**

Not classified based on available information.

### Components:

### **Ertugliflozin:**

Routes of exposure : Oral

Target Organs : Kidney, Stomach, Prostate

Assessment : May cause damage to organs through prolonged or repeated

exposure.

## Repeated dose toxicity

## **Components:**

### metformin hydrochloride:

Species : Rat
NOAEL : 125 mg/kg
Application Route : Oral
Exposure time : 1 year

Remarks : No significant adverse effects were reported

Species : Rabbit
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 1 Year

Remarks : No significant adverse effects were reported

Species: DogNOAEL: 50 mg/kgApplication Route: Subcutaneous

Exposure time : 2 year

Remarks : No significant adverse effects were reported

### Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

## Magnesium stearate:

Species : Rat

NOAEL : > 100 mg/kg Application Route : Ingestion Exposure time : 90 Days

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Remarks : Based on data from similar materials

**Ertugliflozin:** 

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species : Rat

LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 30 d
Target Organs : Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d

Target Organs : Kidney, Bone, Stomach

Species : Rat LOAEL : 25 mg/kg Exposure time : 90 d

Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog NOAEL : 150 mg/kg Application Route : Oral Exposure time : 270 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 28 d
Target Organs : Bone

Remarks : No significant adverse effects were reported

## **Aspiration toxicity**

Not classified based on available information.

### **Experience with human exposure**

## **Components:**

## metformin hydrochloride:

Skin contact : Remarks: May irritate skin.

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Diarrhea, Nausea, Vomiting, Gastrointestinal dis-

comfort, flatulence, asthenia, Fatigue, Headache

**Ertugliflozin:** 

Ingestion : Symptoms: The most common side effects are:, Headache,

constipation, Diarrhea, Nausea, urinary tract infection, muscle

pain, upper respiratory tract infection

#### **SECTION 12. ECOLOGICAL INFORMATION**

### **Ecotoxicity**

### **Components:**

### metformin hydrochloride:

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 40 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l

Exposure time: 48 h Method: DIN 38412

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 1 mg/l

Exposure time: 47 h

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

EL50 (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l

Exposure time: 16 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

**Ertugliflozin:** 

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 2.14 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: 5.2 04/14/2025

SDS Number: 590547-00020

Date of last issue: 09/30/2023 Date of first issue: 04/01/2016

Method: OECD Test Guideline 209

Persistence and degradability

**Components:** 

metformin hydrochloride:

Biodegradability : Result: rapidly degradable

Biodegradation: 50 % Exposure time: 2 hrs

Cellulose:

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable

Remarks: Based on data from similar materials

**Ertugliflozin:** 

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 40.8 % Exposure time: 28 d

**Bioaccumulative potential** 

**Components:** 

metformin hydrochloride:

Partition coefficient: n-

octanol/water

: log Pow: -2

Magnesium stearate:

Partition coefficient: n-

: log Pow: > 4

octanol/water

**Ertugliflozin:** 

Partition coefficient: n-

log Pow: 2.47

octanol/water

Mobility in soil

Components:

metformin hydrochloride:

Distribution among environ-

log Koc: 4.3

mental compartments

Method: OECD Test Guideline 106

**Ertugliflozin:** 

Distribution among environ-

mental compartments

log Koc: 2.88

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 5.2 04/14/2025 590547-00020 Date of first issue: 04/01/2016

#### Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14. TRANSPORT INFORMATION**

### **International Regulations**

#### **UNRTDG**

Not regulated as a dangerous good

#### **IATA-DGR**

Not regulated as a dangerous good

### **IMDG-Code**

Not regulated as a dangerous good

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### **Domestic regulation**

#### **TDG**

Not regulated as a dangerous good

### Special precautions for user

Not applicable

### **SECTION 15. REGULATORY INFORMATION**

## The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## **SECTION 16. OTHER INFORMATION**

## Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 09/30/2023 04/14/2025 590547-00020 Date of first issue: 04/01/2016 5.2

CA QC OEL Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA 8-hour, time-weighted average CA AB OEL / TWA 8-hour Occupational exposure limit 8-hour time weighted average CA BC OEL / TWA

CA QC OEL / TWAEV Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified: Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

compile the Material Safety

**Data Sheet** 

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date 04/14/2025 Date format mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified

according to the Hazardous Products Regulations



# **Ertugliflozin / Metformin Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 09/30/2023

 5.2
 04/14/2025
 590547-00020
 Date of first issue: 04/01/2016

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8